To date the platform model has wildly garnered private investment and IPO launches, as well as enticed talent.

While most of the funding for biotech startups developing novel therapeutics has stalled in the past year as VCs take a more conservative approach and focus on companies already generating revenue through multiple streams, demand for therapies has not decreased.

Over the last decade, professionals working in the Life Sciences understand that change has been the only constant.